Chemoprevention efficacy is a function of a drug’s ability to clear existing sub-patent malaria infections and to prevent new infections over the desired period of protection (at least 28 days). This study presents a novel protocol to determine if sub-optimal protection occurs with adherence to a three-day regimen of sulfadoxine-pyrimethamine and amodiaquine (SPAQ), the antimalarials commonly used in seasonal malaria chemoprevention (SMC), and, if it occurs, whether it results from drug resistance or low drug exposure.
This poster was presented at the 72nd annual meeting of the American Society of Tropical Medicine and Hygiene.
Country: MozambiqueKeywords: ASTMH | Research | Malaria | Resistance management | SMC
« Back to Publications